Motor complications in Parkinson's disease

International Journal of Neuroscience

Volumn 121, Issue SUPPL. 2, 2011, Pages 37-44

  Ondo, William G ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Dyskinesia; Fluctuations; Motor complications; Parkinson; Surgery

Indexed keywords

AMANTADINE; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CLOZAPINE; DEXTROMETHORPHAN; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; ETIRACETAM; LEVODOPA; MEMANTINE; MONOAMINE OXIDASE B INHIBITOR; PERGOLIDE; PRAMIPEXOLE; QUETIAPINE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TOLCAPONE;

ANTICHOLINERGIC SYNDROME; APPLICATION SITE IRRITATION; ARTICLE; BODY FLUID; BRAIN DEPTH STIMULATION; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE COURSE; DOPAMINERGIC ACTIVITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; DYSKINESIA; EDEMA; ERGOT SIDE EFFECT; HUMAN; HYPOTENSION; IMPULSE CONTROL DISORDER; LIVEDO RETICULARIS; LIVER FAILURE; MOTOR DYSFUNCTION; NAUSEA; NEUROSURGERY; PARKINSON DISEASE; PSYCHOSIS; SIDE EFFECT; STOMATITIS; UNSPECIFIED SIDE EFFECT; VOMITING;

DRUG ADMINISTRATION SCHEDULE; DYSKINESIA, DRUG-INDUCED; HUMANS; HYPOKINESIA; LEVODOPA; PARKINSON DISEASE;

EID: 80155150254     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2011.620198     Document Type: Article

References (48)

1. Nutt JG. Motor fluctuations and dyskinesia in Parkinsons disease. Parkinsonism Relat Disord. 2001;8(2):101-8. (Pubitemid 32728023)
2. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K; Parkinson Study Group. Levodopa and the progression of Parkinsons disease. N Engl J Med. 2004;351(24):2498-508.
3. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, Abdalla M; 056 Study Group. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord. 2006;21(11):1844-50. (Pubitemid 44848929)
4. Andersson I, Granerus AK, Jagenburg R, Svanborg A. Intestinal decarboxylation of orally administered L-dopa. Influence of pharmacological preparations, dose magnitude, dose sequence and food intake. Acta Med Scand. 1975;198(5):415-20.
5. Olanow CW, Gauger LL, Cedarbaum JM. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinsons disease. Ann Neurol. 1991;29(5):556-9.
6. Cedarbaum JM, Olanow CW. Dopamine sulfate in ventricular cerebrospinal fluid and motor function in Parkinsons disease. Neurology. 1991;41(10):1567-70.
7. Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesias in Parkinsons disease phenomenology and pathophysiology. Mov Disord. 1994;9(1):2-12. (Pubitemid 24022609)
8. Calabresi P, Di Filippo M, Ghiglieri V, Tambasco N, Picconi B. Levodopa-induced dyskinesias in patients with Parkinsons disease: filling the bench-to-bedside gap. Lancet Neurol. 2010;9(11):1106-17.
9. de la Fuente-Fernandez R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, Ruth TJ, Stoessl AJ. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinsons disease: implications for dyskinesias. Brain. 2004;127(Pt 12):2747-54. (Pubitemid 39627382)
10. Colosimo C, Merello M, Hughes AJ, Sieradzan K, Lees AJ.Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinsons disease: implications for the pathogenesis of the on-off phenomenon. J Neurol Neurosurg Psychiatry. 1996;60(6):634-7. (Pubitemid 26237114)
11. Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, Fisone G, Cenci MA, Calabresi P. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci. 2003;6(5):501-6. (Pubitemid 36514698)
12. Mouradian MM, Heuser IJ, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinsons disease. Ann Neurol. 1990;27(1):18-23. (Pubitemid 20031354)
13. Stocchi F, RascolO,KieburtzK, Poewe W, Jankovic J,Tolosa E, Barone P, Lang AE, Olanow CW. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010;68(1):18-27.
14. Koller WC, Hutton JT, Tolosa E, Capilldeo R. Immediaterelease and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology. 1999;53(5):1012-9. (Pubitemid 29442117)
15. Ondo WG, Shinawi L, Moore S. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: a single-dose, double-blind, doubledummy, placebo-controlled, crossover trial. Mov Disord. 2010;25(16):2724-7.
16. Karlsborg M, Korbo L, Regeur L, Glad A. Duodopa pump treatment in patients with advanced Parkinsons disease. Dan Med Bull. 2010;57(6):A4155.
17. Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J,WeinerWJ; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidencebased review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66(7):983-95. (Pubitemid 44044780)
18. Entacapone improves motor fluctuations in levodopa-treated Parkinsons disease patients. Parkinson Study Group. Ann Neurol. 1997;42(5):747-55.
19. Adler CH, Singer C, OBrien C, Hauser RA, Lew MF, Marek KL, Dorflinger E, Pedder S, Deptula D, Yoo K. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopacarbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol. 1998;55(8):1089-95. (Pubitemid 28367234)
20. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62(2):241-8.
21. Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM. Zydis selegiline reduces off time in Parkinsons disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord. 2004;19(4):426-32. (Pubitemid 38559645)
22. Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL EASE-PD Adjunct Study Investigators. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology. 2007;68(14):1108-15. (Pubitemid 46559844)
23. Chen JJ, Obering C. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinsons disease. Clin Ther. 2005;27(11):1710-24. (Pubitemid 41815224)
24. Pfeiffer RF, Gutmann L, Hull KL Jr, Bottini PB, Sherry JH. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinsons disease. Parkinsonism Relat Disord. 2007;13(2):93-100. (Pubitemid 46343617)
25. Garcia Ruiz PJ, Sesar Ignacio A, Ares Pensado B, Castro García A, Alonso Frech F, Alvarez López M, Arbelo González J, Baiges Octavio J, Burguera Hernández JA, Calopa Garriga M, Campos Blanco D, Castaño García B, Carballo CorderoM, Chacón Peña J, Espino Ibáñez A,Gorospe Onisalde A, Giménez-Roldán S, Granés Ibáñez P, Hernández Vara J, Ibáñez Alonso R, Jiménez Jiménez FJ,Krupinski J,Kulisevsky Bojarsky J, Legarda Ramírez I, Lezcano García E, Martínez-Castrillo JC, Mateo González D, Miquel Rodríguez F, Mir P, Muñoz Fargas E, Obeso Inchausti J, Olivares Romero J, Olivé Plana J, Otermin Vallejo P, Pascual Sedano B, Pérez de Colosía Rama V, Pérez López-Fraile I, Planas Comes A, Puente Periz V, Rodríguez Oroz MC, Sevillano García D, Solís Pérez P, Suárez Muñoz J, Vaamonde Gamo J, Valero Merino C, Valldeoriola Serra F, Velázquez Pérez JM, Yáñez Baña R, Zamarbide Capdepon I. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinsons disease with motor fluctuations: a multicenter study. Mov Disord. 2008;23(8):1130-6.
26. Magazanik LG, Antonov SM, Lukomskaya N, Potapèva NN, Gmiro VE, Johnson J. Blockade of glutamate-and cholinergic ion channels by amantadine derivatives. Neurosci Behav Physiol. 1996;26(1):13-22. (Pubitemid 126722660)
27. Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV,Chase TN, Bonuccelli U. Intravenous amantadine improves levodopa-induced dyskinesias: an acute double-blind placebocontrolled study. Mov Disord. 2001;16(3):515-20. (Pubitemid 36041158)
28. da Silva-Junior FP, Braga-Neto P, Sueli Monte F, de Bruin VM. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study. Parkinsonism Relat Disord. 2005;11(7):449-52. (Pubitemid 41526996)
29. Sawada H, Oeda T, Kuno S, Nomoto M, Yamamoto K, Yamamoto M, Hisanaga K, Kawamura T; Amantadine Study Group. Amantadine for dyskinesias in Parkinsons disease: a randomized controlled trial. PLoS One. 2010;5(12):e15298.
30. Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K, Leroi I, Pozo-Rodriguez F, Minthon L, Londos E. Memantine in patients with Parkinsons disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009;8(7):613-8.
31. Ondo WG, Shinawi L, Davidson A, Lai D.Memantine for nonmotor features of Parkinsons disease: a double-blind placebocontrolled exploratory pilot trial. Parkinsonism Relat Disord. 2011;17(3):156-9.
32. Emre M, TsolakiM, Bonuccelli U, Destée A, Tolosa E, Kutzelnigg A, Ceballos-Baumann A, Zdravkovic S, Bladstr öm A, Jones R; 11018 Study Investigators. Memantine for patients with Parkinsons disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969-77.
33. Varanese S, Howard J, Di Rocco A. NMDA antagonist memantine improves levodopa-induced dyskinesias and on-off phenomena in Parkinsons disease. Mov Disord. 2010;25(4):508-10.
34. Verhagen Metman L, Del Dotto P, Natte R, van den Munckhof P, Chase TN. Dextromethorphan improves levodopainduced dyskinesias in Parkinsons disease. Neurology. 1998;51(1):203-6. (Pubitemid 28345384)
35. Durif F, Debilly B, Galitzky M, Morand D, Viallet F, Borg M, Thobois S, Broussolle E, Rascol O. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology. 2004;62(3):381-8. (Pubitemid 38200847)
36. Pierelli F, Adipietro A, Soldati G, Fattapposta F, Pozzessere G, Scoppetta C. Low dosage clozapine effects on L-dopainduced dyskinesias in parkinsonian patients. Acta Neurol Scand. 1998;97(5):295-9. (Pubitemid 28191920)
37. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinsons disease.NEngl J Med. 1999;340(10):757-63.
38. Wolz M, Lohle M, Strecker K, Schwanebeck U, Schneider C, Reichmann H, Grählert X, Schwarz J. Levetiracetam for levodopa-induced dyskinesia in Parkinsons disease: a randomized, double-blind, placebo-controlled trial. J Neural Transm. 2010;117(11):1279-86.
39. Wong KK, Alty JE, Goy AG, Raghav S, Reutens DC, Kempster PA. A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinsons disease. Mov Disord. 2011;26(8):1552-5.
40. Stathis P, Konitsiotis S, Tagaris G, Peterson D. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinsons disease. Mov Disord. 2011;26(2):264-70.
41. Lai EC, Jankovic J, Krauss JK, Ondo WG, Grossman RG. Long-term efficacy of posteroventral pallidotomy in the treatment of Parkinsons disease. Neurology. 2000;55(8): 1218-22.
42. Ondo WG, Silay Y, Almaguer M, Jankovic J. Subthalamic deep brain stimulation in patients with a previous pallidotomy. Mov Disord. 2006;21(8):1252-4. (Pubitemid 44336622)
43. Ondo WG, Bronte-Stewart H. The North American survey of placement and adjustment strategies for deep brain stimulation. Stereotact Funct Neurosurg. 2005;83(4):142-7. (Pubitemid 41797951)
44. Bronstein JM, Tagliati M, Alterman RL, Lozano AM, Volkmann J, Stefani A, Horak FB, Okun MS, Foote KD, Krack P, Pahwa R, Henderson JM, Hariz MI, Bakay RA, Rezai A,Marks WJ Jr, Moro E, Vitek JL, Weaver FM, Gross RE, DeLong MR. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol. 2011;68(2):165.
45. Lang AE, Houeto JL, Krack P, Kubu C, Lyons KE, Moro E, Ondo W, Pahwa R, Poewe W, Tr öster AI, Uitti R, Voon V. Deep brain stimulation: preoperative issues. Mov Disord. 2006;21 Suppl 14:S171-96. (Pubitemid 44028281)
46. Williams A, Gill S, Varma T, Jenkinson C, Quinn N, Mitchell R, Scott R, Ives N, Rick C, Daniels J, Patel S, Wheatley K; PD SURG Collaborative Group. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinsons disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol. 2010;9(6):581-91.
47. Follett KA, Weaver FM, Stern M, Hur K, Harris CL, Luo P, Marks WJ Jr, Rothlind J, Sagher O, Moy C, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein JM, Stoner G, Starr PA, Simpson R, Baltuch G, De Salles A, Huang GD, Reda DJ; CSP 468 Study Group. Pallidal versus subthalamic deep-brain stimulation for Parkinsons disease. N Engl J Med. 2010;362(22):2077-91.
48. Kenney C, Simpson R, Hunter C, Ondo W, Almaguer M, Davidson A, Jankovic J. Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. J Neurosurg. 2007;106(4):621-5. (Pubitemid 46536458)